Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 222,828,415 papers from all fields of science
Search
Sign In
Create Free Account
latanoprost
Known as:
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate
, latanoprost [Chemical/Ingredient]
, Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
Expand
A prostaglandin F2alpha analogue and a prostanoid selective FP receptor agonist with an ocular hypertensive effect. Latanoprost increases uveoscleral…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
10 relations
Broader (2)
Antihypertensive Agents
Prostaglandins F, Synthetic
Glaucoma, Open-Angle
Prostaglandins
analogs & derivatives
latanoprost / Timolol
Narrower (4)
PHXA41
PhXA34
Xalatan
latanoprost 0.05 MG/ML Ophthalmic Solution
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
Comparison of invasive and non-invasive tonometry in the mouse.
Christy A. Morris
,
J. Crowston
,
J. Lindsey
,
J. Danias
,
R. Weinreb
Experimental Eye Research
2006
Corpus ID: 23881351
2006
2006
The state of being noninferior.
D. Musch
,
B. Gillespie
Ophthalmology (Rochester, Minn.)
2006
Corpus ID: 30625183
Highly Cited
2005
Highly Cited
2005
Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation.
T. Ota
,
Hiroshi Murata
,
Ei-ichiro Sugimoto
,
M. Aihara
,
M. Araie
Investigative Ophthalmology and Visual Science
2005
Corpus ID: 10183849
PURPOSE To establish a mouse model for the pharmacological analysis of antiglaucoma drugs, considering the effect of variations…
Expand
Highly Cited
2004
Highly Cited
2004
A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma.
A. Alm
,
J. Schoenfelder
,
J. McDermott
A M A Archives of Ophthalmology
2004
Corpus ID: 24879267
OBJECTIVE To evaluate the 5-year safety and efficacy of adjunctive 0.005% latanoprost once daily. METHODS Patients with primary…
Expand
Highly Cited
1999
Highly Cited
1999
Cost considerations of medical therapy for glaucoma.
R. Fiscella
,
Jennifer L Geller
,
Leanna L Gryz
,
J. Wilensky
,
M. Viana
American journal of ophthalmology-glaucoma
1999
Corpus ID: 43300690
Highly Cited
1999
Highly Cited
1999
Intraocular Pressure-Lowering Effects of Latanoprost Monotherapy versus Latanoprost or Pilocarpine in Combination with Timolol
M. G. Bucci
1999
Corpus ID: 36827801
PurposeTo compare intraocular pressure (IOP) after adding either latanoprost or pilocarpine to timolol treatment or switching to…
Expand
Highly Cited
1999
Highly Cited
1999
The effect of once-daily latanoprost on intraocular pressure and pulsatile ocular blood flow in normal tension glaucoma
M. Mckibbin
,
M. Menage
Eye
1999
Corpus ID: 12186940
Purpose To determine the effect of once-daily 0.005% latanoprost on intraocular pressure (IOP) and pulsatile ocular blood flow…
Expand
Highly Cited
1997
Highly Cited
1997
Prostaglandin-induced iridial pigmentation in primates.
G. Selén
,
J. Stjernschantz
,
B. Resul
Survey of ophthalmology
1997
Corpus ID: 2710086
Review
1997
Review
1997
Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids.
B. Resul
,
J. Stjernschantz
,
G. Selén
,
Laszlo Z. Bito
Survey of ophthalmology
1997
Corpus ID: 22495985
Highly Cited
1994
Highly Cited
1994
Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure.
Alexander H. Rulo
,
E. Greve
,
Philip F. J. Hoyng
British Journal of Ophthalmology
1994
Corpus ID: 10187353
A randomised observer masked clinical study was conducted to assess the additive effect of latanoprost (13,14-dihydro-17-phenyl…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE